Avonex Kit
Product Images NDC 59627-333

Product Visual Gallery

This gallery contains 66 technical images submitted to the FDA as part of the official labeling for Avonex (NDC 59627-333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biogen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Avo08 0026 01)

A Kaplan-Meier survival curve chart titled 'Time to Onset of Sustained Disability Progression in Patients with MS in Study 1.' The x-axis represents weeks up to 104, and the y-axis shows the percentage of patients progressing up to 50%. Two curves compare AVONEX and placebo groups, with AVONEX at 22% progression and placebo at 35%. A p-value of 0.02 is noted on the chart.*

FDA Label Image

Figure 2 (Avo08 0026 02)

A bar graph titled 'Confirmed Change in EDSS from Study Entry to End of Study 1' comparing percentage of patients on Avonex and placebo across confirmed change categories in baseline EDSS scores. The x-axis shows categories from -1.0 or less (better) to 2.0 or more (worse), and the y-axis indicates percentage of patients. Avonex and placebo groups are shown with black and gray bars respectively, illustrating distribution differences with a p-value of 0.006.*

FDA Label Image

Figure 3 (Avo08 0026 03)

A Kaplan-Meier curve titled "Time to onset of a Second Exacerbation in Study 2," comparing Avonex and placebo groups over a 36-month period. The y-axis shows the percentage of patients with a second exacerbation, and the x-axis represents time in months. The Avonex group shows a lower percentage of patients experiencing a second exacerbation compared to placebo. The number of subjects at risk is provided at intervals for both groups. Statistical values include a p-value of 0.002 and a rate ratio of 0.56.*

FDA Label Image

Figure (Avo08 0026 04)

Instructional diagram showing parts of the Avonex Pen injection device. Labeled components include the blue activation button, tamper-evident cap, injector shield with grooved area, body of the pen, needle cover with foil, and Avonex Pen cover. This image aids in understanding the pen's assembly and use features.*

FDA Label Image

Figure (Avo08 0026 05)

An instructional illustration showing a hand holding the Avonex Pen injection device. The image highlights the pen's injection area near the top tip, suggesting preparation or use before administration.*

FDA Label Image

Figure (Avo08 0026 06)

An instructional illustration showing hands preparing the Avonex Pen injection device. One hand is holding the pen, and the other hand is pulling a purple tab from the device in preparation for use.*

FDA Label Image

Figure (Avo08 0026 07)

An illustration showing a close-up of a glass syringe tip after attachment. The glass syringe tip is highlighted and labeled, demonstrating the correct positioning or attachment on a medical device component, likely related to injection preparation.*

FDA Label Image

Figure (Avo08 0026 08)

An instructional illustration showing a hand holding an Avonex Pen injection device, with a close-up of the pen's needle cover being twisted off to prepare for intramuscular injection. This visual aids in demonstrating the proper removal of the needle cover before administration.*

FDA Label Image

Figure (Avo08 0026 09)

An instructional illustration showing a person preparing an Avonex Pen injection, solution for intramuscular use, by removing the pen's cap as a preparatory step before injection.*

FDA Label Image

Figure (Avo08 0026 10)

An instructional illustration showing hands preparing an Avonex Pen for intramuscular injection. One hand holds the pen vertically, while the other hand twists a purple cap or safety device at the base of the pen, likely indicating a step in readying the injection device for use.*

FDA Label Image

Figure (Avo08 0026 11)

An instructional illustration showing a close-up view of an Avonex Pen autoinjector device attached to a forearm, demonstrating the step "After (attached needle)" for intramuscular injection of Interferon Beta-1a solution.*

FDA Label Image

Figure (Avo08 0026 12)

An instructional illustration demonstrating hands holding the Avonex Pen injectable device, with one hand preparing the pen for injection by removing the outer cover. The image focuses on device use steps for the Avonex Pen (Interferon Beta-1a) injection, solution, 30 mcg/0.5 mL.*

FDA Label Image

Figure (Avo08 0026 13)

An instructional illustration showing a hand holding an Avonex Pen injection device with an arrow indicating an upward motion to extend the pen before use. The text below the image reads 'After (extended),' demonstrating the pen's state after being prepared for injection.*

FDA Label Image

Figure (Avo08 0026 14)

The image shows a close-up view of the safety lock feature on an Avonex Pen, an intramuscular injection device for Interferon Beta-1a 30 mcg/0.5 mL by Biogen Inc. The safety lock is clearly visible, indicating a focus on user safety mechanisms in the pen design.*

FDA Label Image

Figure (Avo08 0026 15)

The image shows a portion of an Avonex Pen injection device labeled for Interferon Beta-1a, 30 mcg/0.5 mL, by Biogen Inc. The visible feature is an oval medicine display window on the pen, which allows viewing of the medication inside before administration. The background is white with the display window outlined in blue.*

FDA Label Image

Figure (Avo08 0026 16)

An anatomical illustration showing the correct placement of an intramuscular injection in the upper thigh. The image highlights the injection site with a red oval on the lateral thigh, demonstrating where the Avonex Pen injection should be administered intramuscularly.*

FDA Label Image

Figure (Avo08 0026 17)

Illustration showing the proper technique for intramuscular injection, depicting a hand holding a syringe administering an injection into the upper thigh area of a leg. The image highlights the injection site and method.*

FDA Label Image

Figure (Avo08 0026 18)

An instructional illustration depicting the intramuscular injection site on the upper outer arm near the shoulder. The image highlights the deltoid muscle area with a purple arrow and markings, demonstrating where to administer the injection for the Avonex Pen, which contains Interferon Beta-1a 30 mcg/0.5 mL.*

FDA Label Image

Figure (Avo08 0026 19)

An illustration showing a close-up of a cylindrical injector device with a labeled circular display window, likely part of the Avonex Pen for intramuscular injection.*

FDA Label Image

Figure (Avo08 0026 20)

An illustration showing a hand holding a syringe poised to inject into the outer thigh area of a human leg. A purple arrow points to the injection site on the upper lateral thigh region. The image demonstrates the correct intramuscular injection site for the Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL solution.*

FDA Label Image

Figure (Avo08 0026 21)

An instructional illustration showing two states of the Avonex Pen safety lock mechanism. The left image shows the safety lock visible and engaged, while the right image shows the safety lock released and not visible in the window. This diagram helps users understand how to identify if the safety lock is active on the Avonex Pen injection device.*

FDA Label Image

Figure (Avo08 0026 22)

An instructional illustration showing the proper technique for administering an intramuscular injection using the Avonex Pen. It depicts a person holding the Avonex Pen near the thigh, demonstrating the angle and position for injection on the outer thigh area.*

FDA Label Image

Figure (Avo08 0026 23)

An illustration of a blue stopwatch displaying "10 sec" in white text at its center, indicating a 10-second timing interval.*

FDA Label Image

Figure (Avo08 0026 24)

An instructional illustration showing the proper hand position for administering an injection. The left side shows a foot being held with two hands, and the right side shows a hand holding a syringe with an arrow pointing from the foot image to the syringe, indicating the injection site location or administration method.*

FDA Label Image

Figure (Avo08 0026 25)

Illustration of an Avonex Pen injection device with a circular display window highlighted, showing the injection mechanism and a blue grip area. The image focuses on the pen's design for delivering Interferon Beta-1a, 30 mcg/0.5 mL intramuscular injection by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 26)

An instructional illustration showing a hand holding an Avonex Pen injection device with a downward-pointing arrow indicating the direction for injecting the medication. The image visually guides the user on how to position or operate the injection pen for administering Interferon Beta-1a intramuscularly.*

FDA Label Image

Figure (Avo08 0026 27)

The image shows an Avonex Pen injection device, used for intramuscular administration of Interferon Beta-1a, 30 micrograms per 0.5 mL solution. It is a prefilled pen with a white body featuring ridged grips and an orange indicator. The product is labeled by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 28)

An instructional diagram showing parts of the Avonex Pen injection system, including the syringe, cap, and protective rubber cover. The illustration clarifies key components of the intramuscular injection device for Avonex Pen, which contains Interferon Beta-1a 30 mcg/0.5 mL solution.*

FDA Label Image

Figure (Avo08 0026 29)

Illustration showing a hand holding an injection pen, designed for intramuscular administration of Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL solution. The image focuses on the proper grip of the prefilled pen for injection.*

FDA Label Image

Figure (Avo08 0026 30)

Instructional illustration showing hands holding an Avonex Pen prefilled injection device. One hand grips the pen, and the other hand is positioning the cap for removal. The image demonstrates handling of the Avonex Pen injection device, which delivers 30 mcg/0.5 mL interferon beta-1a intramuscularly, labeled by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 31)

An instructional diagram showing the removal of a gray cap, indicated by a purple curved arrow, from the top of an Avonex Pen injection device. The pen is designed for intramuscular injection of Interferon Beta-1a 30 mcg/0.5 mL, manufactured by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 32)

An instructional illustration showing removal of the needle cover from a syringe. The top image shows the needle cover alone. The bottom image depicts hands holding a syringe with a glass syringe tip, with an arrow indicating downward movement to remove the needle cover.*

FDA Label Image

Figure (Avo08 0026 33)

An instructional illustration showing hands preparing an Avonex Pen for intramuscular injection. One hand holds the syringe while the other removes the needle cover. The image is related to the administration of Interferon Beta-1a, 30 mcg/0.5 mL solution by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 34)

An illustration showing the front and side views of a human leg. Both views highlight the upper outer thigh region with a red square, indicating the recommended injection site for an intramuscular injection.*

FDA Label Image

Figure (Avo08 0026 35)

An illustration showing the correct injection site for an intramuscular injection on the upper arm. The marked area is highlighted in red on the deltoid muscle, indicating where the Avonex Pen injection is to be administered.*

FDA Label Image

Figure (Avo08 0026 36)

An instructional illustration showing hands preparing an injection. It depicts a syringe being filled or assembled and an arrow indicating the next step, likely guiding the assembly or use process for the Avonex Pen injection solution.*

FDA Label Image

Figure (Avo08 0026 37)

An instructional illustration showing a hand holding a syringe at a 90-degree angle above the upper arm of another person, indicating an intramuscular injection technique for Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL solution.*

FDA Label Image

Figure (Avo08 0026 38)

An instructional illustration showing how to use the Avonex Pen for intramuscular injection. The image depicts a hand pressing the plunger of the pen into a person's arm, highlighting the injection process for the Avonex Pen containing Interferon Beta-1a.*

FDA Label Image

Figure (Avo08 0026 39)

An instructional illustration showing proper technique for intramuscular injection. The image depicts a hand holding a syringe at a 90-degree angle above the upper arm, indicating the injection site and needle positioning for administering the Avonex Pen injection.*

FDA Label Image

Figure (Avo08 0026 40)

An instructional illustration showing parts of a syringe used for injection. Labeled components include the Syringe, Cap, and Protective Rubber Cover. The syringe appears to be prefilled and is intended for use with the Avonex Pen injection system.*

FDA Label Image

Figure (Avo08 0026 41)

Illustration showing a hand holding an Avonex Pen injection device. The pen is designed for intramuscular administration of Interferon Beta-1a injection solution at a strength of 30 mcg/0.5 mL, manufactured by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 42)

An instructional illustration showing how to hold the Avonex Pen injection device. The image depicts two hands: one holding the pen and the other supporting it, with a red arrow indicating the motion or direction for use, likely demonstrating the twisting or unlocking action of the pen before injection.*

FDA Label Image

Figure (Avo08 0026 43)

An instructional diagram illustrating the removal or attachment of a cap or cover from an Avonex Pen injector device. It shows the pen device and a cap being lifted off or placed with a curved red arrow indicating the direction of movement.*

FDA Label Image

Figure (Avo08 0026 44)

An instructional illustration showing a hand holding an Avonex Pen injection device and another hand pulling off the protective cap from the pen. A red arrow indicates the upward motion to remove the cap from the injection pen.*

FDA Label Image

Figure (Avo08 0026 45)

Illustration showing hands preparing an Avonex Pen prefilled injection device for use. The image demonstrates the proper grip and handling of the syringe with the needle cap being removed, emphasizing injection preparation technique for intramuscular administration.*

FDA Label Image

Figure (Avo08 0026 46)

Avonex Pen injection solution dose indicator display showing intramuscular injection dosages of Interferon Beta-1a. The image features three color-coded dose markers labeled 1/4 Dose (white), 1/2 Dose (yellow), and 3/4 Dose (purple) for weeks 1, 2, and 3 respectively, illustrating dose escalation over time. The product is labeled by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 47)

An illustration diagram showing a close-up of an Avonex Pen component labeled 'collar.' The image focuses on the top part of the injection device where the collar is located, highlighting a detailed view of this part of the pen used for delivering Interferon Beta-1a solution intramuscularly.*

FDA Label Image

Figure (Avo08 0026 48)

Avonex Pen 30 mcg/0.5 mL injection, solution in a prefilled autoinjector syringe. The image shows the pen device used for intramuscular administration of Interferon Beta-1a. It is a clear syringe with visible measurement markings and a gray plunger.*

FDA Label Image

Figure (Avo08 0026 49)

Avonex Pen 30 mcg/0.5 mL injection solution for intramuscular use by Biogen Inc., shown as a yellow prefilled pen device for administration.*

FDA Label Image

Figure (Avo08 0026 50)

Avonex Pen 30 mcg/0.5 mL injection solution in a prefilled pen device. The Pen is for intramuscular administration and features a purple-colored body with a clear cap. The labeler shown is Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 51)

An instructional illustration showing the proper removal of the protective needle shield from an Avonex Pen autoinjector. The diagram highlights the pen device and the shield being pulled away to expose the needle for intramuscular injection.*

FDA Label Image

Figure (Avo08 0026 52)

An illustration of the Avonex Pen, a prefilled injection device containing Interferon Beta-1a 30 mcg/0.5 mL solution. The image shows the pen’s syringe body, plunger, and attached needle, designed for intramuscular injection. The pen features a window to view the solution inside and a clear cap over the needle.*

FDA Label Image

Figure (Avo08 0026 53)

An instructional illustration showing a prefilled Avonex Pen injection device with arrows indicating the operation or usage steps. The device is designed for intramuscular injection of Interferon Beta-1a solution at a strength of 30 micrograms per 0.5 mL.*

FDA Label Image

Figure (Avo08 0026 54)

An instructional illustration showing hands adjusting the dose on an Avonex Pen injection device. The image focuses on the dial mechanism indicating a 1/2 dose selection, demonstrating preparation for intramuscular injection of Interferon Beta-1a 30 mcg/0.5 mL solution by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 55)

Diagram showing the area on the thigh recommended for intramuscular injection, indicating the middle outer section of the thigh. The illustration displays front and side views of a leg with a red square highlighting the injection site, relevant to injection administration guidance.*

FDA Label Image

Figure (Avo08 0026 56)

An illustration showing the recommended intramuscular injection site on the upper arm. The target injection area is highlighted in red on the outer part of the upper arm muscle, demonstrating proper placement for medication administration.*

FDA Label Image

Figure (Avo08 0026 57)

An illustration showing hands preparing an Avonex Pen injection. One hand holds the pen device while the other hand removes the needle cap, indicated by a red arrow pointing outward from the pen. This diagram demonstrates part of the injection preparation process for Avonex Pen 30 mcg/0.5 mL intramuscular solution by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 58)

An instructional illustration showing a hand holding an Avonex Pen prefilled syringe labeled for Interferon Beta-1a 30 mcg/0.5mL intramuscular injection, with an arrow indicating the direction to press the syringe into the skin on the forearm.*

FDA Label Image

Figure (Avo08 0026 59)

Illustration showing a hand holding an Avonex Pen, an intramuscular injection pen for delivering Interferon Beta-1a at a strength of 30 micrograms per 0.5 mL, designed for human prescription use by Biogen Inc.*

FDA Label Image

Figure (Avo08 0026 60)

An instructional illustration showing a hand holding an Avonex Pen injection device. The pen is positioned above the skin with a red arrow pointing upward, indicating the motion or action related to use, likely depicting the step to remove or prepare the pen for intramuscular injection of Interferon Beta-1a.*

FDA Label Image

Figure (Avo08 0026 61)

A table outlining a dosing schedule over four weeks for a medication. It lists the week number, corresponding dose fraction (from one-quarter dose in Week 1 to full dose in Week 4), the color of the titration device used (White, Yellow, Purple, or None), and a blank column for date/time entries.*

FDA Label Image

Principal Display Panel (30 mcg Carton Label)

Packaging label for Avonex Pen injection, solution 30 mcg/0.5 mL single-dose prefilled autoinjector by Biogen Inc. The label states it is for intramuscular injection once a week, provided as an Administration Dose Pack. Storage and handling instructions, caution about natural rubber latex, and dispensing guidelines are included on the label.*

FDA Label Image

Principal Display Panel (30 mcg Carton Label)

The packaging label for Avonex Pen, an injection solution of Interferon Beta-1a at 30 mcg/0.5 mL strength in a single-dose prefilled syringe for intramuscular injection. The label features Biogen Inc. as the manufacturer and includes dosage guidance indicating use once a week. The label also notes storage instructions, active ingredient details, and cautionary statements regarding latex and allergenic potential.*

FDA Label Image

Principal Display Panel (Carton Label)

Avonex Pen 30 mcg/0.5 mL prefilled autoinjector injection for intramuscular use, containing interferon beta-1a. The label shows a carton for 4 Avonex Pen Administration Dose Packs, each delivering a single dose once a week. Manufactured by Biogen Inc., the packaging includes storage instructions, barcodes, and additional product details.*

FDA Label Image

Principal Display Panel (Carton Label)

Avonex Pen (interferon beta-1a) injection 30 mcg/0.5 mL single-dose prefilled syringe for intramuscular injection, packaged in administration dose packs. The label includes storage instructions, a caution about natural rubber latex allergy, contents details, and manufacturer information for Biogen Inc. The product is intended for once-a-week use.*

FDA Label Image

Principal Display Panel (Tray Lid Label)

Label for Avonex Pen (Interferon Beta-1a) 30 mcg/0.5 mL single-dose prefilled syringe for intramuscular injection. The label includes storage instructions (2°C to 8°C), a note about natural rubber latex, and contact information for Biogen Inc., Cambridge, MA. U.S. License #1697 and NDC 59627-002-07 are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.